Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic NK-Cell Transplantation for Mooren's Ulcer
NCT07782138Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Nov 2027
01
Overview
Open-label, single-arm trial of allogeneic natural killer cells in Mooren's ulcer. Primary endpoint: Change in central corneal thickness at 48 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
allogeneic natural killer cells
03
Conditions
Mooren's ulcer
Beyond the preview
Go deeper on NCT07782138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07782138.